For the quarter ending 2025-09-30, BLGO made $1,103,000 in revenue. -$6,479,000 in net income. Net profit margin of -587.40%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue from contract with customer, including assessed tax | 1,103,000 | 2,777,000 | 3,269,000 | 4,207,000 |
| Product | 418,000 | 907,000 | - | - |
| Service | 313,000 | 449,000 | - | - |
| Cost of goods and services sold | 731,000 | 1,356,000 | 1,781,000 | 2,210,000 |
| Gross profit | 372,000 | 1,421,000 | 1,488,000 | 1,997,000 |
| Selling, general and administrative expenses | 3,088,000 | 2,688,000 | 2,559,000 | 2,402,500 |
| Research and development | 615,000 | 535,000 | 791,000 | 784,500 |
| Credit loss expense | 3,849,000 | - | - | - |
| Total operating expenses | 7,552,000 | 3,223,000 | 3,350,000 | 3,187,000 |
| Operating loss | -7,180,000 | -1,802,000 | -1,862,000 | -1,190,000 |
| Interest expense | 144,000 | -80,000 | -65,000 | -11,333.333 |
| Grant income | - | - | - | 6,500 |
| Interest income | 80,000 | - | - | - |
| Ppp loan forgiveness | 0 | 0 | - | 0 |
| Finance fee | - | - | - | 53,833.333 |
| Grant income | 0 | 0 | 6,000 | - |
| Total other expense | -64,000 | -80,000 | -59,000 | -4,000 |
| Net loss | -7,244,000 | -1,882,000 | -1,921,000 | -1,253,500 |
| Net loss attributable to noncontrolling interest | -765,000 | -690,000 | -766,000 | -541,500 |
| Net loss attributable to common shareholders | -6,479,000 | -1,192,000 | -1,155,000 | -712,000 |
| Loss per share attributable to shareholders basic and diluted (in dollars per share) | -0.02 | -0.004 | -0.004 | -0.004 |
| Weighted average number of common shares outstanding (in shares) | 308,974,027 | 303,196,989 | 301,274,243 | -149,401,402 |
BIOLARGO, INC. (BLGO)
BIOLARGO, INC. (BLGO)